Faculty Profiles - katsuyama eri

Papers - katsuyama eri

Division display 41 - 60 of about 103 ／ All the affair displays >>

Pharmacologic inhibition of PARP5, but not that of PARP1 or 2, promotes cytokine production and osteoclastogenesis through different pathways. International journal

Yosuke Asano, Yoshinori Matsumoto, Fang He, Takayuki Katsuyama, Eri Katsuyama, Shigetomo Tsuji, Hiroshi Kamioka, Jose La Rose, Robert Rottapel, Jun Wada

Clinical and experimental rheumatology 41 ( 9 ) 1735 - 1745 2023.1

Language：English Publishing type：Research paper (scientific journal)

OBJECTIVES: PARPs, which are members of the poly(ADP-ribose) polymerase superfamily, promote tumorigenesis and tumour-associated inflammation and are thus therapeutic targets for several cancers. The aim of the present study is to investigate the mechanistic insight into the roles PARPs for inflammation. METHODS: Primary murine macrophages were cultured in the presence or absence of the PARP5 inhibitor NVP-TNKS656 to examine the role of PARP5 for cytokine production. RESULTS: In contrast to the roles of other PARPs for induction of inflammation, we found in the present study that pharmacologic inhibition of PARP5 induces production of inflammatory cytokines in primary murine macrophages. We found that treatment with the PARP5 inhibitor NVP-TNKS656 in macrophages enhanced steady-state and LPS-mediated cytokine production through degradation of IκBα and subsequent nuclear translocation of NF-κB. We also found that pharmacologic inhibition of PARP5 stabilises the adaptor protein 3BP2, a substrate of PARP5, and that accelerated cytokine production induced by PARP5 inhibition was rescued in 3BP2-deleted macrophages. Additionally, we found that LPS increases the expression of 3BP2 and AXIN1, a negative regulator of β-catenin, through suppression of PARP5 transcripts in macrophages, leading to further activation of cytokine production and inhibition of β-catenin-mediated cell proliferation, respectively. Lastly, we found that PARP5 inhibition in macrophages promotes osteoclastogenesis through stabilisation of 3BP2 and AXIN1, leading to activation of SRC and suppression of β-catenin, respectively. CONCLUSIONS: Our results show that pharmacologic inhibition of PARP5 against cancers unexpectedly induces adverse autoinflammatory side effects through activation of innate immunity, unlike inhibition of other PARPs.

DOI： 10.55563/clinexprheumatol/qf55h8

PubMed

researchmap

A case of sitosterolaemia-caused systemic large-vessel stenosis mimicking Takayasu arteritis in which FDG-PET provided a clue for the differential diagnosis

Takato Nakadoi, Eri Katsuyama, Kazuya Matsumoto, Kenta Shidahara, Kei Hirose, Shoichi Nawachi, Yosuke Asano, Yu Katayama, Yoshia Miyawaki, Takayuki Katsuyama, Mariko Takano-Narazaki, Yoshinori Matsumoto, Ken-Ei Sada, Hayato Tada, Jun Wada

Rheumatology Advances in Practice 7 ( 3 ) 2023.1

Grit personality of physicians and achievement of treatment goals in patients with systemic lupus erythematosus. International journal

Ken-Ei Sada, Yoshia Miyawaki, Kenta Shidahara, Shoichi Nawachi, Yu Katayama, Yosuke Asano, Keigo Hayashi, Keiji Ohashi, Eri Katsuyama, Takayuki Katsuyama, Mariko Takano-Narazaki, Yoshinori Matsumoto, Nao Oguro, Yuichi Ishikawa, Natsuki Sakurai, Chiharu Hidekawa, Ryusuke Yoshimi, Dai Kishida, Takanori Ichikawa, Yasuhiro Shimojima, Noriaki Kurita, Nobuyuki Yajima

Rheumatology (Oxford, England) 62 ( 6 ) 2154 - 2159 2022.10

Language：English Publishing type：Research paper (scientific journal)

OBJECTIVES: Although personality characteristics of patients with systemic lupus erythematosus (SLE) affect their disease activity and damage, it is unclear whether those of attending physicians affect the outcomes of patients with SLE. Grit is a personality trait for achieving long-term goals that may influence the decision-making for continuing treatment plans for patients. We aimed to evaluate the relationship between the grit of attending physicians and achievement of treatment goals in patients with SLE. METHODS: This cross-sectional study was conducted at five referral hospitals. The main exposure was "consistency of interest" and "perseverance of effort" of the attending physicians, measured by the Short Grit Scale. The primary outcome was achievement of a lupus low disease activity state (LLDAS). The association between physicians' grit score and LLDAS was analyzed by generalized estimating equation (GEE) logistic regression with cluster robust variance estimation with adjustment for confounders. RESULTS: The median (interquartile range) total, consistency, and perseverance scores of 37 physicians were 3.1 (2.9-3.6), 3.3 (2.8-3.8), and 3.3 (3.0-3.5), respectively. Among the 386 patients, 154 (40%) had achieved LLDAS. Low consistency score (≤2.75) in physicians was related to LLDAS achievement independently using GEE logistic regression. The score of the question "I often set a goal but later choose to pursue a different one" was significantly higher in patients achieving LLDAS. CONCLUSIONS: Difficulty of attending physicians to change treatment goals might be related to lower LLDAS achievement in patients with SLE.

DOI： 10.1093/rheumatology/keac612

PubMed

researchmap

A case of recurrent IgG4-related disease successfully treated with belimumab after remission of systemic lupus erythematosus. International journal

Yu Katayama, Takayuki Katsuyama, Kenta Shidahara, Shoichi Nawachi, Yosuke Asano, Keiji Ohashi, Yoshia Miyawaki, Eri Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Ken-Ei Sada, Jun Wada

Rheumatology (Oxford, England) 61 ( 10 ) e308-e310 2022.10

Association of one-point glucocorticoid-free status with chronic damage and disease duration in systemic lupus erythematosus: a cross-sectional study. International journal

Ken-Ei Sada, Yu Katayama, Yosuke Asano, Keigo Hayashi, Yoshia Miyawaki, Keiji Ohashi, Eri Katsuyama, Takayuki Katsuyama, Mariko Takano-Narazaki, Yoshinori Matsumoto, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Nobuyuki Yajima

Lupus science & medicine 9 ( 1 ) 2022.9

Language：English Publishing type：Research paper (scientific journal)

OBJECTIVE: It is still unclear how glucocorticoids (GCs) affect the long-term clinical course of patients with SLE. The objective of this study is to explore the factors associated with GC-free treatment status. METHODS: Using data from the lupus registry of nationwide institutions, GC dose at registration was compared between short, middle and long disease durations of <5, 5-20 and ≥20 years, respectively. After excluding patients who never used GC, we evaluated the relationship between GC-free status and chronic damage using Systemic Lupus International Collaborating Clinics Damage Index. RESULTS: GC doses at enrolment of the 1019 patients were as follows: GC-free in 101 (10%); 0<prednisolone (PSL) ≤5 mg/day in 411 (40%); 5<PSL ≤7.5 in 169 (17%); 7.5<PSL ≤10 in 194 (19%) and PSL≥10 in 144 (14%) patients. Of the patients who were not currently using GCs, patients who never used GC more frequently had short disease duration (66% with short, 23% with middle and 17% with long disease duration, p=0.00029). Univariate analysis of patients who underwent GC treatment showed that patients without GCs exhibited older age, lower disease activity, less immunosuppressant and hydroxychloroquine use and higher C3 levels. Among patients with a disease duration of ≥20 years, GC-free status was more frequent in patients without chronic damage (11% vs 4%, p=0.023). After adjusting for age, sex and disease activity, no chronic damage accrual was associated with GC-free status (OR 3.6, 95% CI 1.1 to 11.3). CONCLUSION: Even in the patients with long disease duration, one-point GC-free treatment status might be related to no chronic damage accrual.

DOI： 10.1136/lupus-2022-000772

PubMed

researchmap

CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy. International journal

Ping-Min Chen, Eri Katsuyama, Abhigyan Satyam, Hao Li, Jose Rubio, Sungwook Jung, Sylvia Andrzejewski, J David Becherer, Maria G Tsokos, Reza Abdi, George C Tsokos

Science advances 8 ( 24 ) eabo4271 2022.6

Language：English Publishing type：Research paper (scientific journal)

Infection is one of the major causes of mortality in patients with systemic lupus erythematosus (SLE). We previously found that CD38, an ectoenzyme that regulates the production of NAD+, is up-regulated in CD8+ T cells of SLE patients and correlates with the risk of infection. Here, we report that CD38 reduces CD8+ T cell function by negatively affecting mitochondrial fitness through the inhibition of multiple steps of mitophagy, a process that is critical for mitochondria quality control. Using a murine lupus model, we found that administration of a CD38 inhibitor in a CD8+ T cell-targeted manner reinvigorated their effector function, reversed the defects in autophagy and mitochondria, and improved viral clearance. We conclude that CD38 represents a target to mitigate infection rates in people with SLE.

DOI： 10.1126/sciadv.abo4271

PubMed

researchmap

関節リウマチの増悪との鑑別に苦慮した両側踵脆弱性骨折の1例

氏家正皓, 片山祐, 松本和也, 廣瀬啓, 志田原健太, 縄稚翔一, 中土井崇人, 浅野洋介, 大橋敬司, 宮脇義亜, 勝山恵理, 勝山隆行, 楢崎真理子, 佐田憲映, 松本佳則, 中原龍一, 那須義久, 西田圭一郎, 和田淳

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 753 - 753 2022.3

IgG4関連肥厚性硬膜炎に重篤な視力障害を来たし視神経周囲炎が示唆された一例

上舞直, 宮脇義亜, 松本和也, 中土井崇人, 大橋敬司, 廣瀬啓, 縄稚翔一, 志田原健太, 浅野洋介, 片山祐, 勝山恵理, 勝山隆行, 楢崎真理子, 松本佳則, 佐田憲映, 和田淳

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 754 - 754 2022.3

初発から40年後に診断に至った炎症症候持続TNF受容体関連周期性症候群の一例

高嶋香菜子, 松本佳則, 松本和也, 廣瀬啓, 志田原健太, 縄稚翔一, 中土井崇人, 浅野洋介, 片山祐, 大橋敬司, 宮脇義亜, 勝山恵理, 勝山隆行, 楢崎真理子, 佐田憲映, 和田淳

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 756 - 756 2022.3

Clinical manifestations of SLE SLE患者における代診医師への受診と主治医への信頼度との関連性 TRUMP2-SLEの横断研究(The Association of the visits to substitute physicians and trust in one's physician in SLE patients: a cross-sectional TRUMP2-SLE study)

Katayama Yu, Miyawaki Yoshia, Shidahara Kenta, Nawachi Shoichi, Asano Yosuke, Ohashi Keiji, Katsuyama Eri, Katsuyama Takayuki, Narazaki Mariko, Matsumoto Yoshinori, Sada Ken-ei, Oguro Nao, Yajima Nobuyuki, Yoshimi Ryusuke, Shimojima Yasuhiro, Wada Jun, Kurita Nobuaki

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 503 - 503 2022.3

痛風性関節炎、特発性間質性肺炎発症後に多発脳梗塞を呈した顕微鏡的多発血管炎(MPA)の1例

堀口裕紀, 松本佳則, 松本和也, 廣瀬啓, 志田原健太, 縄稚翔一, 中土井崇人, 浅野洋介, 片山祐, 宮脇義亜, 勝山恵理, 勝山隆行, 楢崎真理子, 佐田憲映, 和田淳

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 756 - 756 2022.3

SLEにおける疾患活動性とQOL SLE患者の健康関連QOL指標の解釈を可能にする最小重要差の検討前向きコホート研究から登録時記述疫学

松本和也, 宮脇義亜, 志田原健太, 縄稚翔一, 浅野洋介, 片山祐, 大橋敬司, 勝山恵理, 勝山隆行, 楢崎真理子, 松本佳則, 佐田憲映, 柳井亮, 矢嶋宣幸, 高谷亜由子, 一瀬邦弘, 和田淳

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 367 - 367 2022.3

横隔膜挙上に伴う呼吸困難を合併した巨細胞性動脈炎(GCA)の一例

松岡雅人, 松本佳則, 松本和也, 廣瀬啓, 志田原健太, 縄稚翔一, 中土井崇人, 浅野洋介, 片山祐, 大橋敬司, 宮脇義亜, 勝山恵理, 勝山隆行, 楢崎真理子, 佐田憲映, 和田淳

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 755 - 755 2022.3

COVID-19ワクチン接種後に脊椎関節炎が顕在化した一例

志田原健太, 松本佳則, 松本和也, 廣瀬啓, 中土井崇人, 縄稚翔一, 浅野洋介, 片山祐, 大橋敬司, 宮脇義亜, 勝山恵理, 勝山隆行, 楢崎真理子, 佐田憲映, 和田淳

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 627 - 627 2022.3

IgG4関連肥厚性硬膜炎に重篤な視力障害を来たし視神経周囲炎が示唆された一例

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 754 - 754 2022.3

高安動脈炎が疑われたがPET-CTを契機に希少疾患であるシトステロール血症と判明した一例

中土井崇人, 勝山恵理, 松本和也, 廣瀬啓, 志田原健太, 縄稚翔一, 浅野洋介, 片山祐, 宮脇義亜, 大橋敬司, 勝山隆行, 楢崎真理子, 松本佳則, 佐田憲映, 和田淳

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 672 - 672 2022.3

動眼神経麻痺を発症した巨細胞性動脈炎の一例

清水崇司, 勝山隆行, 松本和也, 廣瀬啓, 志田原健太, 縄稚翔一, 中土井崇人, 浅野洋介, 片山祐, 大橋敬司, 宮脇義亜, 勝山恵理, 楢崎真理子, 佐田憲映, 松本佳則, 和田淳

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 755 - 755 2022.3

爪形成不全と肘関節脱臼を伴った関節リウマチの1例

増田倫敦, 松本佳則, 松本和也, 廣瀬啓, 志田原健太, 縄稚翔一, 中土井崇人, 浅野洋介, 片山祐, 大橋敬司, 宮脇義亜, 勝山恵理, 勝山隆行, 楢崎真理子, 佐田憲映, 和田淳

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 754 - 754 2022.3

大型血管炎が疑われた大動脈周囲悪性リンパ腫の1例

道廣麻友, 勝山隆行, 松本和也, 廣瀬啓, 志田原健太, 縄稚翔一, 中土井崇人, 浅野洋介, 片山祐, 大橋敬司, 宮脇義亜, 勝山恵理, 楢崎真理子, 佐田憲映, 松本佳則, 和田淳

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 756 - 756 2022.3

SLEにおける疾患活動性とQOL 全身性エリテマトーデス診療における医師の性格特性と治療目標達成との関連 TRUMP2-SLE研究

佐田憲映, 宮脇義亜, 志田原健太, 縄稚翔一, 浅野洋介, 片山祐, 大橋敬司, 勝山隆行, 勝山恵理, 楢崎真理子, 松本佳則, 小黒奈緒, 矢嶋宣幸, 吉見竜介, 下島恭弘, 栗田宜明

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 367 - 367 2022.3

　 PREV - NEXT 　

< katsuyama eri >

Papers - katsuyama eri